Consultant Rheumatology, Unity Health Medical Center(2020-Current)
Director of Rheumatology, White River Medical Center(2015-2020)
A Phase III Randomized, Double Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of “Study Drug” in Patients with Systemic Lupus Erythematosus 2022
A Phase 2a, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered :”Study Drug A” and “Study Drug B” Combination Therapy in Participants with Active Psoriatic Arthritis 2022
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of “Study Drug” Administered Subcutaneously in Participants with Active Psoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor α Agent 2023
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of “Study Drug” Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease 2023
| 2024 | Excellence in Rheumatology, AY Magazine |
| 2018 | Nominated to Leading Physicians of The World |
| 2017 | Inducted as Fellow to American College of Physicians |
| 2012-2013 |
Teaching Fellow of the Year Division of Geriatrics, Department of Medicine University of Maryland, Baltimore, MD |
Please be aware that the services offered on this platform are with U.S. physicians via a virtual 2nd opinion service. Diagnosis may differ when the physician has had the opportunity to provide an in-person examination. The absence of the in-person examinations can affect the accuracy of the diagnosis and resulting opinion. Please also be aware that a virtual 2nd opinion will not establish a provider-patient relationship. The provide patient relationship can only be established when the patient signs a consent to treatment form in the physician’s physical clinic location in the United States.
